Drug intelligence / Profile preview

BRVT323

Development stage: Preclinical
Lead developer: Biorevert
Modality: Small Molecules

Overview

BRVT323 is a preclinical-stage small molecule (New Chemical Entity) developed by Biorevert, a South Korean biotechnology company. It is designed using Biorevert's proprietary Cell Reversion Technology, which aims to transform malignant cancer cells back into a normal or dormant state by modulating complex gene regulatory networks rather than simply killing them. The drug is being investigated for the treatment of various solid tumors, including colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), glioblastoma (GBM), and melanoma.

Beyond the preview

Go deeper on BRVT323.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRVT323.

Explore the full profile